YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.